This x-ray of the pelvis shows an electronic nerve-stimulating device in the right iliac fossa. The procedure is ideal in this population because it is minimally invasive and highly efficacious The ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

BARCELONA—Sacral neuromodulation (SNM) with Interstim Therapy is significantly better than an additional trial of standard medical treatment (SMT) for patients with refractory overactive bladder (OAB) ...

The US Food and Drug Administration (FDA) has approved Neuspera Medical’s integrated sacral neuromodulation (iSNM) system for treating urinary urge incontinence (UUI). The California-based company’s ...

A 41-year-old nurse from Severance shopping for a solution to her overactive bladder symptoms found a way to regain full control thanks to an innovative procedure. Sarah Avrech said goodbye to a life ...

Neuspera Medical’s percutaneous sacral neuromodulation (pSNM) has hit the “gold standard”, with 84.2% of patients suffering ...

Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...

PARK CITY, Utah--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in implantable Tibial Neuromodulation (iTNM) and developer of the Revi® System, a patient-centric solution for urge urinary ...

Boston Scientific is growing its urology portfolio with a $3.7 billion deal to acquire Axonics, makers of neurostimulation therapies for urinary and fecal incontinence. Currently a chief competitor in ...

Electrical transcutaneous neuromodulation (eTNM) of the peroneal nerve led to fewer side effects compared with solifenacin (Vesicare) in the treatment of overactive bladder, a randomized trial showed.